Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort - Archive ouverte HAL Access content directly
Journal Articles Breast Year : 2020

Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

(1) , (1) , (1) , (2, 3) , (4, 5) , (6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (17) , (18) , (19) , (2) , (20) , (21) , (20) , (1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
Matthieu Carton
Coraline Dubot
  • Function : Author
  • PersonId : 1068941
Anthony Gonçalves
  • Function : Author
  • PersonId : 934200
Tahar Guesmia
  • Function : Author
Thomas Bachelot
  • Function : Author
  • PersonId : 860824
Mathieu Robain
  • Function : Author
Paul Cottu
  • Function : Author
  • PersonId : 921521

Abstract

Background: Young age is a poor prognostic factor in early stage breast cancer (BC) but its value is less established in metastatic BC (MBC). We evaluated the impact of age at MBC diagnosis on overall survival (OS) across three age groups (<40, 40 to 60 and > 60 years(y)). Methods: ESME MBC database is a national cohort, collecting retrospective data from 18 participating French cancer centers between January 01, 2008 and December 31, 2014. Results: Among 14 403 women included, 1077 (7.5%), 6436 (44.7%) and 6890 (47.8%) pts were <40, 40-60 and > 60 y respectively. Pts <40 had significantly more aggressive presentations than other age groups: more frequent HER2+ (25.7 vs 15.3% in >60y) and triple negative subtypes (27.4 vs 14.6% in >60y), and more frequent visceral involvement (36.3 vs 29.8% in >60y). At a median follow-up of 48 months, median OS differed across age groups: 38.8, 38.4 and 35.6 months for pts <40, 40-60 and > 60y, respectively (p < 0.0001). Compared to pts <40y, older pts had a statistically significant higher risk of death (all causes of death included), although of limited clinical value (HR = 1.1, IC 95%:1.01-1.20). There was a significant trend for better OS in pts <40y with HER2+ and luminal diseases. A possible explanation is a greater use of anti-Her2 therapies as first-line treatments: 86.6, 81.9 and 74.9% for pts <40, 40-60 and > 60y, respectively (p < 0.0001). Conclusion: Although young age seems associated with more aggressive presentations at diagnosis of MBC, it has no deleterious effect on OS in this large series.
Fichier principal
Vignette du fichier
1-s2.0-S096097762030103X-main.pdf (810.85 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-02888009 , version 1 (20-05-2022)
hal-02888009 , version 2 (02-06-2022)

Licence

Attribution - NoDerivatives - CC BY 4.0

Identifiers

Cite

Sophie Frank, Matthieu Carton, Coraline Dubot, Mario Campone, Barbara Pistilli, et al.. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort. Breast, 2020, 52, pp.50-57. ⟨10.1016/j.breast.2020.04.009⟩. ⟨hal-02888009v2⟩
200 View
39 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More